MAP2K5 and lung carcinoma: It is also relevant to mention that analyses of the TCGA PanCancer Atlas study (n = 1144) revealed mutation frequencies of 0.6% and 0.9% in MEK5 and ERK5, respectively, in lung cancer patients.